Search Result

Results for "

FGFR2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	FGFR (116) ADC Payload (1) Akt (7) Anaplastic lymphoma kinase (ALK) (1) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (21) Aurora Kinase (2) c-Fms (3) c-Kit (1) c-Myc (1) Caspase (3) CDK (1) Cytochrome P450 (2) DNA/RNA Synthesis (2) Drug Metabolite (1) Drug-Linker Conjugates for ADC (2) E3 Ligase Ligand-Linker Conjugates (1) EGFR (3) Endogenous Metabolite (4) ERK (8) FAK (1) Ferroptosis (1) FLT3 (4) GSK-3 (1) HDAC (1) Interleukin Related (1) IRE1 (1) Isotope-Labeled Compounds (2) JAK (1) Microtubule/Tubulin (1) mRNA (1) mTOR (1) p38 MAPK (3) PD-1/PD-L1 (1) PDGFR (8) PERK (2) PROTAC Linkers (1) PROTACs (5) Pyroptosis (1) Reactive Oxygen Species (ROS) (4) Reference Standards (11) RET (1) SHP2 (1) Small Interfering RNA (siRNA) (3) Src (7) TGF-beta/Smad (1) TNK1 (1) Topoisomerase (1) VEGFR (13)
By Research Areas:	Cancer (118) Cardiovascular Disease (4) Endocrinology (1) Infection (1) Inflammation/Immunology (5) Neurological Disease (3)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) mRNA (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

128

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

GMP Molecules

Targets Recommended: FGFR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13311

Infigratinib Maximum Cited Publications 47 Publications Verification BGJ-398; NVP-BGJ398	FGFR Apoptosis	Cancer
Infigratinib (BGJ-398; NVP-BGJ398) is a potent inhibitor of the *FGFR* family with IC₅₀s of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for *FGFR1, FGFR2, FGFR3, and FGFR4*, respectively.

HY-N0183

Formononetin Maximum Cited Publications 24 Publications Verification Biochanin B; Flavosil; Formononetol	FGFR Apoptosis	Cardiovascular Disease Cancer
Formononetin is a potent *FGFR2* inhibitor with an IC₅₀ of ~4.31 μM. Formononetin potently inhibits angiogenesis and tumor growth .

HY-N0060

Ferulic acid 15+ Cited Publications Coniferic acid	FGFR Endogenous Metabolite	Infection Neurological Disease Cancer
Ferulic acid is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC₅₀s of 3.78 and 12.5 μM for *FGFR1* and *FGFR2*, respectively.

HY-100818

Futibatinib 5+ Cited Publications TAS-120	FGFR	Cancer
Futibatinib (TAS-120) is an orally bioavailable, highly selective, and irreversible *FGFR* inhibitor, with IC₅₀s of 3.9, 1.3, 1.6, and 8.3 nM for FGFR 1-4, respectively. Futibatinib inhibits mutant and wild-type FGFR2 with similar IC₅₀s (wild-type FGFR2=0.9 nM; V5651=1-3 nM; N550H=3.6 nM; E566G=2.4 nM) ^[2] .

HY-109099

Pemigatinib 20+ Cited Publications INCB054828	FGFR	Cancer
Pemigatinib (INCB054828) is an orally active, selective *FGFR* inhibitor with IC₅₀s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma ^[2].

HY-13330

Fexagratinib 30+ Cited Publications AZD4547; ADSK091	FGFR	Cancer
Fexagratinib (AZD4547; ADSK091) is a potent inhibitor of the *FGFR* family with IC₅₀s of 0.2 nM, 2.5 nM, 1.8 nM, and 165 nM for *FGFR1, FGFR2, FGFR3, and FGFR4*, respectively.

HY-147250

Lirafugratinib 1 Publications Verification RLY-4008	FGFR	Cancer
Lirafugratinib (RLY-4008) is an orally active, irreversible and highly selective *FGFR2* inhibitor with an IC₅₀ of 3 nM. Lirafugratinib covalently binds to Cys491. Lirafugratinib targets FGFR2 primary alterations and resistance mutations and induces tumor regression while sparing other FGFRs .

HY-13304

LY2874455 3 Publications Verification	FGFR	Cancer
LY2874455 is a *pan-FGFR* inhibitor with IC₅₀s of 2.8, 2.6, 6.4, 6 nM for *FGFR1, FGFR2, FGFR3, FGFR4*, respectively.

HY-13034

Gandotinib 4 Publications Verification LY2784544	JAK FLT3 FGFR VEGFR	Cancer
Gandotinib (LY2784544) is a potent *JAK2* inhibitor with IC₅₀ of 3 nM. Gandotinib (LY2784544) also inhibits FLT3, FLT4, FGFR2, TYK2, and TRKB with IC₅₀ of 4, 25, 32, 44, and 95 nM.

HY-19981

Derazantinib 3 Publications Verification ARQ-087	FGFR	Cancer
Derazantinib (ARQ-087) is an ATP competitive and orally activeFGFR inhibitor (IC₅₀s: 1.8 nM for FGFR2, 4.5 nM for FGFR1 and 3 nM). Derazantinib inhibits FGFR phosphorylation. Derazantinib inhibits tumor growth in multiple xenograft models ^[2].

HY-100019

Rogaratinib 5+ Cited Publications BAY1163877	FGFR	Cancer
Rogaratinib (BAY1163877) is a potent and selective fibroblast growth factor receptor (FGFR) inhibitor. Rogaratinib inhibits FGFRs with IC50s of 11.2 nM (FGFR1), <1 nM (FGFR2), 18.5 nM (FGFR3), 127 nM (VEGFR3/FLT4), 201 nM (FGFR4), respectively ^[2].

HY-10987A

ENMD-2076 4 Publications Verification	Aurora Kinase FLT3 VEGFR FGFR PDGFR Src Apoptosis	Cancer
ENMD-2076 is a multi-targeted kinase inhibitor with IC₅₀s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, *KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα*, respectively.

HY-101466

E7090	FGFR	Cancer
E7090 is an orally available, potent, and selective *FGFR* inhibitor with IC₅₀s of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for *FGFR1/FGFR2/FGFR3/FGFR4*, respectively .

HY-15391

Lucitanib 5+ Cited Publications E-3810	VEGFR FGFR	Cancer
Lucitanib (E-3810) is a novel dual inhibitor of VEGFR and *FGFR, potently and selectively inhibits VEGFR1, VEGFR2, VEGFR3, FGFR1* and *FGFR2* with IC₅₀s of 7 nM, 25 nM, 10 nM, 17.5 nM, and 82.5 nM, respectively ^[2] .

HY-19957

Zoligratinib 3 Publications Verification Debio 1347; CH5183284	FGFR	Cancer
Zoligratinib (Debio 1347) is an orally available and selective *FGFR* inhibitor with IC₅₀s of 9.3, 7.6, and 22 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.

HY-141600

Aprutumab ixadotin BAY 1187982	Antibody-Drug Conjugates (ADCs) FGFR Microtubule/Tubulin Apoptosis	Cancer
Aprutumab ixadotin (BAY 1187982) is the first antibody-drug conjugate (ADC) to target *FGFR2* and the first to use Auristatin-based payload. Aprutumab ixadotin contains a fully human anti-FGFR2 monoclonal antibody (Aprutumab) (HY-P99007) conjugated by lysine side chains to a non-cleavable linker and via this an innovative Auristatin W derivative. Aprutumab ixadotin can be used for the study of advanced solid tumors, such as FGFR2-positive gastric cancer and triple-negative breast cancer ^[2].

HY-147250A

Lirafugratinib hydrochloride 1 Publications Verification RLY-4008 hydrochloride	FGFR	Cancer
Lirafugratinib (RLY-4008) hydrochloride is an orally active, irreversible and highly selective *FGFR2* inhibitor with an IC₅₀ of 3 nM. Lirafugratinib hydrochloride covalently binds to Cys491. Lirafugratinib hydrochloride targets FGFR2 primary alterations and resistance mutations and induces tumor regression while sparing other FGFRs .

HY-18602

FIIN-2	FGFR	Cancer
FIIN-2 is an irreversible inhibitor of *FGFR* with an IC₅₀ of 3.1, 4.3, 27, and 45 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.

HY-N0060A

Ferulic acid sodium 15+ Cited Publications Coniferic acid sodium	FGFR Endogenous Metabolite Reactive Oxygen Species (ROS)	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Ferulic acid sodium is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC₅₀s of 3.78 and 12.5 μM for *FGFR1* and *FGFR2*, respectively.

HY-163985

*PROTAC FGFR2* degrader 1**	PROTACs FGFR Apoptosis	Cancer
PROTAC FGFR2 degrader 1 (compound N5) is a PROTAC that effectively targets FGFR2 with DC₅₀ of 6.46 nM, the *FGFR2* IC₅₀ is 0.08 nM. PROTAC FGFR2 degrader 1 has anti-proliferative activity and highly selective, induces G0/G1 arrest of KATOIII and SNU16 cell cycle and inhibits apoptosis by reducing the activation of p-ERK and p-PLCγ, the downstream proteins of FGFR2. PROTAC FGFR2 degrader 1 inhibits gastric cancer cells remained above 50% at a concentration of 0.17 nM. PROTAC FGFR2 degrader 1 potently inhibits the growth of SNU16 xenograft tumors in mouse model (Structure Note: Pink, FGFR2 activator: HY-18708; Blue, E3 ligase ligand: HY--10984; Black, linker: HY-163989; E3 ligase ligand + linker：HY-163986) .

HY-162865

FGFR2-IN-3	FGFR	Cancer
FGFR2-IN-3 is an inhibitor of fibroblast growth factor receptor 2 (FGFR2). FGFR2-IN-3 has good binding properties, forming key interactions and inducing conformational changes in FGFR2. FGFR2-IN-3 can be used for research on tumors .

HY-P99007

Aprutumab BAY 1179470	FGFR	Cancer
Aprutumab (BAY 1179470) is a fully human fibroblast growth factor receptor 2 (FGFR2)-specific monoclonal antibody . Aprutumab induces *FGFR2* endocytosis and degradation in cancer cells expressing *FGFR2. Aprutumab serves as the targeted monoclonal antibody component of the antibody-drug conjugate BAY 1187982 (HY-141600) and mediates the endocytosis of the antibody-drug conjugate into FGFR2*-positive cells. Aprutumab can be used for the research of *FGFR2*-positive solid tumors, including studies on gastric cancer and triple-negative breast cancer .

HY-165298

DGY-09-192	PROTACs FGFR ERK	Cancer
DGY-09-192 is a PROTAC *FGFR1/2* degrader (FGFR1: DC₅₀ = 4.35 nM; FGFR2: DC₅₀ = 70 nM). DGY-09-192 preferentially degrades wild-type *FGFR1/2* and multiple *FGFR2* fusion proteins (including *FGFR2*-PHGDH and *FGFR2*-OPTN). DGY-09-192 suppresses downstream *FGFR* signaling (reducing phosphorylation of *FRS2* Y196 and *ERK1/2* T202/Y204) in vitro and vivo. DGY-09-192 can be used for the study of FGFR-driven cancers. (Pink: FGFR1/2 ligand (HY-160013), Blue: VHL Ligand (HY-112078), Black: Linker (HY-W020017)) .

HY-P991584

HuGAL-FR21	FGFR	Cancer
HuGAL-FR21 is a humanized antiFGFR2IIIb IgG1 monoclonal antibody. HuGAL-FR21 can block the binding of *FGF2, FGF7, and FGF10* to FGFR2IIIb and inhibit FGF-induced phosphorylation of FGFR2IIIb. HuGAL-FR21 can downregulate the expression of *FGFR2* in SNU-16 cells. HuGAL-FR21 shows the significant anti-tumor activity in athymic nude mice bearing gastric cancer xenograft models. HuGAL-FR21 can be used for research on cancer such as gastric cancer .

HY-17601

Alofanib 4 Publications Verification RPT835	FGFR Apoptosis	Cardiovascular Disease Cancer
Alofanib (RPT835) is a potent and selective allosteric inhibitor of fibroblast growth factor receptor 2 (FGFR2). Anticancer and antiangiogenic activity ^[2].

HY-13311A

Infigratinib phosphate Maximum Cited Publications 47 Publications Verification BGJ-398 phosphate; NVP-BGJ398 phosphate	FGFR	Cancer
Infigratinib phosphate (BGJ-398 phosphate; NVP-BGJ398 phosphate) is a potent inhibitor of the *FGFR* family with IC₅₀ of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for *FGFR1, FGFR2, FGFR3, and FGFR4*, respectively.

HY-148779

FGFR3-IN-5	FGFR	Cancer
FGFR3-IN-5 is a potent and selective *FGFR3* inhibitor with IC₅₀ values of 3, 44, and 289 nM for FGFR3, FGFR2, and FGFR1, respectively. FGFR3-IN-5 can be used in research of cancer .

HY-N0060R

Ferulic acid (Standard) 1 Publications Verification Coniferic acid (Standard)	Reference Standards FGFR Endogenous Metabolite	Cancer
Ferulic acid (Standard) is the analytical standard of Ferulic acid. This product is intended for research and analytical applications. Ferulic acid is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC50s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively.

HY-101768

PRN1371 1 Publications Verification	FGFR c-Fms	Cancer
PRN1371 is a highly selective and potent *FGFR1-4* and CSF1R inhibitor with IC₅₀s of 0.6, 1.3, 4.1, 19.3 and 8.1 nM for FGFR1, FGFR2, FGFR3, FGFR4 and CSF1R, respectively .

HY-156632

Resigratinib KIN-3248	FGFR	Cancer
Resigratinib (KIN-3248) is an irreversible and orally active covalent inhibitor of *FGFR*1-4 that effectively inhibits wild-type and drug-resistant mutations (such as FGFR2 V565F, FGFR3 V555M). Resigratinib covalently binds to the Cys492 site of FGFR, blocks the FGFR signaling pathway, inhibits tumor cell proliferation and induces apoptosis. Resigratinib can be used for the study of FGFR2/3-driven solid tumors (such as cholangiocarcinoma and bladder cancer) ^[2].

HY-175743

TYRA-200	FGFR	Cancer
TYRA-200 is a potent and orally active *FGFR2* inhibitor. TYRA-200 inhibits the kinase activity of wild-type FGFR2 and its mutants. TYRA-200 induces significant tumor regression in FGFR2-driven cancer models. TYRA-200 can be used for the research of FGFR2-altered advanced solid tumors, intrahepatic cholangiocarcinoma, and endometrial cancer ^[2].

HY-145231

FGFR2-IN-2	FGFR	Cancer
FGFR2-IN-2 (Compound 38) is a selective *FGFR2* inhibitor with IC₅₀s of 389, 29, and 758 nM for FGFR1, FGFR2, and FGFR3, respectively .

HY-149843

LC-MB12	FGFR PROTACs	Cancer
LC-MB12 is an orally active PROTAC compound targets *FGFR2* degradation with a DC₅₀ of 11.8 nM. LC-MB12 contains BGJ398 (a FGFR2 inhibitor), PROTAC linker and CRBN.LC-MB12 inhibits *FGFR2* signaling in gastric cancer cells and has anti-tumor activity .

HY-145230

FGFR2-IN-1	FGFR	Others
FGFR2-IN-1 is a selective *FGFR2* inhibitor with an IC₅₀ of 140 nM.

HY-N0183R

Formononetin (Standard) Biochanin B (Standard); Flavosil (Standard); Formononetol (Standard)	Reference Standards FGFR Apoptosis	Cardiovascular Disease Cancer
Formononetin (Standard) is the analytical standard of Formononetin. This product is intended for research and analytical applications. Formononetin is a potent FGFR2 inhibitor with an IC50 of ~4.31 μM. Formononetin potently inhibits angiogenesis and tumor growth .

HY-100818R

Futibatinib (Standard) TAS-120 (Standard)	Reference Standards FGFR	Cancer
Futibatinib (Standard) is the analytical standard of Futibatinib. This product is intended for research and analytical applications. Futibatinib (TAS-120) is an orally bioavailable, highly selective, and irreversible *FGFR* inhibitor, with IC₅₀s of 3.9, 1.3, 1.6, and 8.3 nM for FGFR 1-4, respectively. Futibatinib inhibits mutant and wild-type FGFR2 with similar IC₅₀s (wild-type FGFR2=0.9 nM; V5651=1-3 nM; N550H=3.6 nM; E566G=2.4 nM) ^[2] .

HY-10987

ENMD-2076 Tartrate 4 Publications Verification	Aurora Kinase FLT3 VEGFR FGFR Src PDGFR Apoptosis	Cancer
ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with IC₅₀s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, *KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα*, respectively.

HY-151903S

FGFR2/3-IN-1	FGFR	Cancer
FGFR2/3-IN-1 is a potent and selective FGFR2 and FGFR3 (FGFR) inhibitor with IC₅₀s of 1 nM and 0.5 nM, respectively. FGFR2/3-IN-1 displays >40-fold selectivity over FGFR1/FGFR4 and other kinome. FGFR2/3-IN-1 also inhibits FGFR3 V555L and V555M mutants with IC₅₀s of 2.7 nM and 6.1 nM, respectively .

HY-P11162

FGF7p	FGFR Akt ERK mTOR Apoptosis	Inflammation/Immunology
FGF7p is a small molecule peptide and a potential bladder protector. FGF7p can activate downstream signaling pathways of *FGFR2* in the urinary tract epithelium (pFRS2α, pAKT and pERK). FGF7p alleviates cyclophosphamide induced apoptosis and tissue damage in urinary tract epithelial cells by activating AKT and its downstream anti apoptotic targets (pBAD, pS6/mTORC1). FGF7p is commonly used in the study of inflammatory conditions .

HY-18603

FIIN-3	EGFR FGFR	Cancer
FIIN-3 is an irreversible inhibitor of *FGFR* with an IC₅₀ of 13.1, 21, 31.4, and 35.3 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.

HY-15391A

Lucitanib dihydrochloride 5+ Cited Publications	VEGFR FGFR	Cancer
Lucitanib (E-3810) dihydrochloride is a novel dual inhibitor of VEGFR and *FGFR, potently and selectively inhibits VEGFR1, VEGFR2, VEGFR3, FGFR1* and *FGFR2* with IC₅₀s of 7 nM, 25 nM, 10 nM, 17.5 nM, and 82.5 nM, respectively ^[2] .

HY-E70823

FGFR2 N549K Recombinant Human Active Protein Kinase	FGFR	Cancer
FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 N549K is a mutant of FGFR3. FGFR2 N549K Recombinant Human Active Protein Kinase is a recombinant FGFR4 N535K protein that can be used to study FGFR4 N535K-related functions .

HY-174974

ISM7594	FGFR	Cancer
ISM7594 is an orally active *FGFR2/3* inhibitor. ISM7594 shows broad-spectrum antiproliferative potency in *FGFR2- or FGFR3*-altered cancer cell panels, including *FGFR2/3* amplification, fusion, and mutation (BaF3-TEL-FGFR2-V564F (IC₅₀ = 0.067 nM), BaF3-TEL-FGFR2-V564I (IC₅₀ = 2 nM)) types. ISM7594 inhibits tumor growth in a dose-dependent manner. ISM7594 can be used for the study of advanced solid tumors with FGFR2/3 aberrations .

HY-RS04916

Fgfr2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Fgfr2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Fgfr2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Fgfr2 Mouse Pre-designed siRNA Set A Fgfr2 Mouse Pre-designed siRNA Set A

HY-174689

*Human FGFR2* mRNA**	mRNA	Cancer
Human FGFR2 mRNA encodes the human fibroblast growth factor receptor 2 (FGFR2) protein, a member of the fibroblast growth factor receptor (FGFR) family. The extracellular portion of FGFR2 protein can interact with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation.

HY-162626

FGFR2 degrader 1	PROTACs FGFR	Cancer
FGFR2 degrader 1 (compound 28E) is a selectively PROTACS degrader of *FGFR2, with the DC₅₀* of 0.645 nM. FGFR2 plays an important role in cancer research (Pink: ligand of target protein; (HY-13304) black: linker; blue: ligand of E3 ligase) .

HY-E70827

FGFR2 V564L Recombinant Human Active Protein Kinase	FGFR	Cancer
FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 V564L is a mutant of FGFR3. FGFR2 V564L Recombinant Human Active Protein Kinase is a recombinant FGFR2 V564L protein that can be used to study FGFR2 V564L-related functions .

HY-E70818

FGFR2 K659M Recombinant Human Active Protein Kinase	FGFR	Cancer
FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 K659M is a mutant of FGFR3. FGFR2 K659M Recombinant Human Active Protein Kinase is a recombinant FGFR2 K659M protein that can be used to study FGFR2 K659M-related functions .

HY-E70815

FGFR2 K526E Recombinant Human Active Protein Kinase	FGFR	Cancer
FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 K526E is a mutant of FGFR3. FGFR2 K526E Recombinant Human Active Protein Kinase is a recombinant FGFR2 K526E protein that can be used to study FGFR2 K526E-related functions .

HY-E70825

FGFR2 V564F Recombinant Human Active Protein Kinase	FGFR	Cancer
FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 V564F is a mutant of FGFR3. FGFR2 V564F Recombinant Human Active Protein Kinase is a recombinant FGFR2 V564F protein that can be used to study FGFR2 V564F-related functions .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0183

Formononetin Maximum Cited Publications 24 Publications Verification Biochanin B; Flavosil; Formononetol	Cardiovascular Disease Classification of Application Fields Astragalus membranaceus var. mongholicus (Bunge)P.K.Hsiao Plants Flavonoids other families Leguminosae Sunscreen Cosmetic Research Glycyrrhiza uralensis Fisch. Disease Research Fields Isoflavones Source Classification	FGFR Apoptosis
Formononetin is a potent *FGFR2* inhibitor with an IC₅₀ of ~4.31 μM. Formononetin potently inhibits angiogenesis and tumor growth .

HY-N0060

Ferulic acid 15+ Cited Publications Coniferic acid	Structural Classification Classification of Application Fields Plants Endogenous metabolite Human Gut Microbiota Metabolites Monophenols other families Simple Phenylpropanols Sunscreen Phenols Phenylpropanoids Cosmetic Research Disease Research Fields Source Classification Cancer	FGFR Endogenous Metabolite
Ferulic acid is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC₅₀s of 3.78 and 12.5 μM for *FGFR1* and *FGFR2*, respectively.

HY-N0060A

Ferulic acid sodium 15+ Cited Publications Coniferic acid sodium	Structural Classification Monophenols other families Classification of Application Fields Simple Phenylpropanols Phenols Phenylpropanoids Plants Endogenous metabolite Disease Research Fields Source Classification Cancer	FGFR Endogenous Metabolite Reactive Oxygen Species (ROS)
Ferulic acid sodium is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC₅₀s of 3.78 and 12.5 μM for *FGFR1* and *FGFR2*, respectively.

HY-N0060R

Ferulic acid (Standard) 1 Publications Verification Coniferic acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Monophenols other families Simple Phenylpropanols Phenols Phenylpropanoids Plants Endogenous metabolite Source Classification	Reference Standards FGFR Endogenous Metabolite
Ferulic acid (Standard) is the analytical standard of Ferulic acid. This product is intended for research and analytical applications. Ferulic acid is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC50s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively.

HY-N7715

Ferulic acid acyl-β-D-glucoside Ferulic acid glucoside; Feruloyl glucose ester	Structural Classification Monophenols Classification of Application Fields Simple Phenylpropanols Rosaceae Other Diseases Phenols Phenylpropanoids Plants Aruncus sylvester Kostel. Disease Research Fields Source Classification	Drug Metabolite
Ferulic acid acyl-β-D-glucoside (Ferulic acid glucoside) is a metabolite of Ferulic Acid (HY-N0060). Ferulic acid acyl-β-D-glucoside can be isolated from flaxseed extract. Ferulic acid is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC₅₀ values of 3.78 and 12.5 μM for *FGFR1* and *FGFR2*, respectively ^[2] .

HY-N0183R

Formononetin (Standard) Biochanin B (Standard); Flavosil (Standard); Formononetol (Standard)	Structural Classification Flavonoids other families Leguminosae Astragalus membranaceus var. mongholicus (Bunge)P.K.Hsiao Plants Glycyrrhiza uralensis Fisch. Isoflavones Source Classification	Reference Standards FGFR Apoptosis
Formononetin (Standard) is the analytical standard of Formononetin. This product is intended for research and analytical applications. Formononetin is a potent FGFR2 inhibitor with an IC50 of ~4.31 μM. Formononetin potently inhibits angiogenesis and tumor growth .

HY-N9507

Picrasidine Q	Alkaloids other families Classification of Application Fields Quinoline Alkaloids Plants Disease Research Fields Indole Alkaloids Source Classification Cancer	Apoptosis FGFR
Picrasidine Q, an alkaloid component extracted from Angelica keiskei species, has the capacity of anti-cell transformation and anti-cancer. Picrasidine Q induces cell apoptosis and G1 phase arrest in human esophageal cancer cell lines, and directly inhibits *FGFR2* kinase activity .

Cat. No.	Product Name	Chemical Structure

HY-151903S

FGFR2/3-IN-1
FGFR2/3-IN-1 is a potent and selective FGFR2 and FGFR3 (FGFR) inhibitor with IC₅₀s of 1 nM and 0.5 nM, respectively. FGFR2/3-IN-1 displays >40-fold selectivity over FGFR1/FGFR4 and other kinome. FGFR2/3-IN-1 also inhibits FGFR3 V555L and V555M mutants with IC₅₀s of 2.7 nM and 6.1 nM, respectively .

HY-13311S

Infigratinib-d3
Infigratinib-d3 is a deuterated analog of infigratinib. Infigratinib is an effective inhibitor of the *FGFR* family, with IC₅₀ values of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for *FGFR1, FGFR2, FGFR3, and FGFR4*, respectively .

HY-N0060S1

Ferulic acid-13C3
Ferulic acid- ¹³C₃ is the ¹³C-labeled Ferulic acid. Ferulic acid is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC50s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively.

HY-W754878

Pemigatinib-d6
Pemigatinib-d₆ (INCB054828-d₆) is deuterium labeled Pemigatinib. Pemigatinib (INCB054828) is an orally active, selective *FGFR* inhibitor with IC₅₀s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma ^[2] .

Targets Recommended: FGFR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10321G

PD173074	FGFR TGF-beta/Smad	Cancer
PD173074 GMP is PD173074 (HY-10321) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. PD173074 is an orally active *FGFR* inhibitor that targets the transphosphorylation of *FGFR1* and *FGFR2* and blocks the FGF signaling pathway. By reducing the phosphorylation level of *SMAD2* and altering the expression of Nodal/Activin target genes, PD173074 eliminates endothelial differentiation potential, thereby inhibiting the formation of capillary-like structures. PD173074 blocks the proliferation and colony formation of tumor cells and increases intratumoral cell apoptosis. PD173074 successfully reverses *FGF-2*-induced chemoresistance to enhance the effect of cisplatin (HY-17394) in small cell lung cancer models. PD173074 can be applied to research related to critical limb ischemia and small cell lung cancer ^[2] .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks